Yousef Tizabi Selected Research

Nicotinic Agonists

1/2020	Nicotine and the nicotinic cholinergic system in COVID-19.
1/2019	Nicotine protects against manganese and iron-induced toxicity in SH-SY5Y cells: Implication for Parkinson's disease.
8/2012	Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease.
5/2008	Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats.
12/2007	Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.
1/2005	Nicotine blocks ethanol-induced apoptosis in primary cultures of rat cerebral cortical and cerebellar granule cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yousef Tizabi Research Topics

Disease

20	Parkinson Disease (Parkinson's Disease) 08/2021 - 11/2005
7	Alcoholism (Alcohol Abuse) 12/2021 - 11/2008
7	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2005
6	Neuroblastoma 12/2021 - 11/2005
5	COVID-19 01/2022 - 01/2020
4	Alzheimer Disease (Alzheimer's Disease) 10/2018 - 12/2003
4	Schizophrenia (Dementia Praecox) 05/2008 - 01/2007
3	Wounds and Injuries (Trauma) 01/2019 - 07/2013
3	Anhedonia 01/2018 - 07/2013
2	Dyskinesias (Dyskinesia) 08/2021 - 01/2017
2	Treatment-Resistant Depressive Disorder 12/2019 - 01/2019
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2019 - 08/2017
2	Neuroinflammatory Diseases 08/2017 - 02/2013
2	Mood Disorders (Mood Disorder) 01/2017 - 10/2004
2	Narcolepsy 10/2007 - 10/2004
2	Tourette Syndrome (Tourette's Syndrome) 08/2005 - 12/2003
2	Tics (Tic) 08/2005 - 12/2003
1	Malnutrition (Nutritional Deficiencies) 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Astrocytoma (Pilocytic Astrocytoma) 01/2019
1	Facies 01/2019
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 12/2018
1	Cognitive Dysfunction 10/2018
1	Substance-Related Disorders (Drug Abuse) 08/2017
1	Genetic Predisposition to Disease (Genetic Predisposition) 08/2017
1	Body Weight (Weight, Body) 11/2016
1	Major Depressive Disorder (Major Depressive Disorders) 12/2014
1	Nervous System Diseases (Neurological Disorders) 12/2014

Drug/Important Bio-Agent (IBA)

17	Nicotine FDA Link 01/2020 - 01/2002
7	salsolinolIBA 10/2020 - 11/2005
7	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2017 - 11/2005
6	Nicotinic AgonistsIBA 01/2020 - 01/2005
6	Neuroprotective AgentsIBA 01/2019 - 11/2005
4	Dopamine (Intropin)FDA LinkGeneric 08/2021 - 07/2007
4	Antidepressive Agents (Antidepressants)IBA 12/2019 - 11/2008
4	Tetanus ToxinIBA 04/2019 - 01/2016
4	NeuropeptidesIBA 01/2019 - 10/2004
4	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 01/2019 - 07/2013
4	Donepezil (Aricept)FDA LinkGeneric 10/2018 - 12/2003
4	Proteins (Proteins, Gene)FDA Link 08/2017 - 12/2009
3	Cholinergic Agents (Cholinergics)IBA 01/2020 - 05/2008
3	Pharmaceutical PreparationsIBA 12/2019 - 07/2014
3	N-Methylaspartate (NMDA)IBA 01/2019 - 01/2007
3	Sucrose (Saccharose)IBA 01/2018 - 07/2013
2	Vitamin D FDA LinkGeneric 01/2022 - 01/2021
2	VitaminsIBA 01/2022 - 01/2021
2	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 12/2021 - 01/2019
2	Kainic Acid Receptors (Kainate Receptor)IBA 12/2021 - 01/2019
2	Ethanol (Ethyl Alcohol)IBA 12/2021 - 01/2003
2	Biological ProductsIBA 01/2021 - 01/2019
2	Butyrates (Butyrate)IBA 10/2020 - 01/2019
2	aminochrome 1 (aminochrome)IBA 01/2019 - 08/2012
2	Amino Acids FDA Link 01/2019 - 07/2017
2	Ketamine FDA LinkGeneric 12/2018 - 01/2018
2	Amphetamine (Amfetamine)FDA LinkGeneric 10/2018 - 08/2017
2	Peptides (Polypeptides)IBA 07/2017 - 01/2016
2	CurcuminIBA 12/2014 - 01/2014
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 10/2009 - 12/2003
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2008 - 12/2007
2	OrexinsIBA 10/2007 - 10/2004
1	FlavonoidsIBA 01/2022
1	dihydromyricetinIBA 01/2022
1	Vitamin K FDA Link 01/2022
1	CoagulantsIBA 01/2022
1	QuercetinIBA 01/2022
1	ZincIBA 01/2022
1	MetalsIBA 01/2022
1	MicronutrientsIBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	AntioxidantsIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2021
1	Dihydroxyphenylalanine (Dopa)IBA 08/2021
1	Ivermectin (Mectizan)FDA Link 01/2020
1	Cholinergic ReceptorsIBA 01/2020
1	Oxidopamine (6 Hydroxydopamine)IBA 01/2020
1	Pramipexole (Mirapex)FDA LinkGeneric 04/2019
1	ManganeseIBA 01/2019
1	IronIBA 01/2019
1	Plant ExtractsIBA 01/2019
1	Trace Elements (Biometals)IBA 01/2019
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019
1	AcetylcholinesteraseIBA 10/2018
1	Methamphetamine (Desoxyn)FDA LinkGeneric 10/2018
1	Caspase 3 (Caspase-3)IBA 10/2018
1	2,3- dioxo- 6- nitro- 7- sulfamoylbenzo(f)quinoxaline (NBQX)IBA 01/2018
1	PolyphenolsIBA 08/2017
1	SynucleinsIBA 08/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 08/2017
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2017
1	Levodopa (L Dopa)FDA LinkGeneric 01/2017
1	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 11/2016
1	LigandsIBA 11/2016
1	MelanocortinsIBA 11/2016
1	sazetidine-AIBA 11/2016
1	1-Methyl-4-phenylpyridinium (1 Methyl 4 phenylpyridinium)IBA 01/2016
1	Nerve Growth Factors (Neurotrophins)IBA 01/2016

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 08/2021 - 04/2009
2	Therapeutics 08/2017 - 01/2017
1	Tobacco Use Cessation Devices 01/2017